COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,137 Articles (22,693 medRxiv, 8,444 bioRxiv)

Most recent first Previous |  Page 1278: Articles 12771-12780  | Next

Predicting SARS-CoV-2 infections for children and youth with single symptom screening
Webster, R. J., Reddy, D., Harrison, M.-A., Farion, K. J., Willmore, J., Foote, M., Thampi, N.
10.1101/2021.08.19.21262310 — Posted: 2021-08-23
Effects of face masks and ventilation on the risk of SARS-CoV-2 respiratory transmission in public toilets: a quantitative microbial risk assessment
Denpetkul, T., Sittipunsakda, O., Pumkaew, M., Mongkolsuk, S., sirikanchana, k.
10.1101/2021.08.21.457245 — Posted: 2021-08-22 Discussion: Onsite
Delta variant and mRNA Covid-19 vaccines effectiveness: higher odds of vaccine infection breakthroughs
Kislaya, I., Rodrigues, E. F., Borges, V., Gomes, J. P., Sousa, C., Almeida, J. P., Peralta-Santos, A., Nunes, B., PT-Covid-19 Group
10.1101/2021.08.14.21262020 — Posted: 2021-08-22 Discussion: Offsite
Anticipating the hospital burden of future COVID-19 epidemic waves
Boennec, C., Alizon, S., Sofonea, M. T.
10.1101/2021.08.19.21262280 — Posted: 2021-08-22
CORONAVIRUS DISEASE 2019 IN A TERTIARY PEDIATRIC CENTER IN PORTUGAL
Milheiro Silva, T., Garcia, A. M., Gouveia, C., Candeias, F., Brito, M. J.
10.1101/2021.08.16.21262100 — Posted: 2021-08-22
Modeling SARS-CoV-2 transmission at a winter destination resort region with high outside visitation
Wu, E. J., Bayham, J., Carlton, E. J., Samet, J. M., Buchwald, A. G.
10.1101/2021.08.18.21262227 — Posted: 2021-08-22
Studies on the level of neutralizing antibodies produced by inactivated COVID-19 vaccines in the real world
Zhang, H., Jia, Y., Ji, Y., Cong, X., Liu, Y., Yang, R., Kong, X., Shi, Y., Zhu, L., Wang, Z., Wang, W., Fei, R., Liu, F., Lu, F., Chen, H., Rao, H.
10.1101/2021.08.18.21262214 — Posted: 2021-08-22
Dynamics of SARS-CoV-2 exposure in Malawian blood donors: a retrospective seroprevalence analysis between January 2020 and February 2021
Mandolo, J., Msefula, J., Henrion, M. Y., Brown, C., Moyo, B., Samon, A., Moyo-Gwete, T., Makhado, Z., Ayres, F., Motlou, T., Mzindle, N., Kalata, N., Muula, A. S., Kwatra, G., Msamala, N., Likaka, A., Mfune, T., Moore, P. L., Mbaya, B., French, N., Heyderman, R. S., Swarthout, T. D., Jambo, K. C.
10.1101/2021.08.18.21262207 — Posted: 2021-08-22
Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY disease (CLARITY): Statistical analysis plan for a randomised controlled Bayesian adaptive sample size trial
McGree, J., Hockham, C., Kotwal, S., Wilcox, A., Bassi, A., Pollock, C., Burrell, L. M., Snelling, T., Jha, V., Jardine, M., Jones, M.
10.1101/2021.08.17.21262196 — Posted: 2021-08-22
Interpreting Wastewater SARS-CoV-2 Results using Bayesian Analysis
Curtis, K., Gonzalez, R. A.
10.1101/2021.08.17.21262165 — Posted: 2021-08-22

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).